DUBLIN and MYSTIC, Conn., Jan. 31, 2011 /PRNewswire/ -- Amarin Corporation plc (Nasdaq: AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today issued a special letter to its shareholders. The text of the letter, written by Joseph S. Zakrzewski, Executive Chairman and Chief Executive Officer of Amarin, follows:

Dear Shareholders:

With 2011 now underway, I am pleased to provide you with a brief review of Amarin's accomplishments in 2010 and an outline of our strategy for 2011 and beyond. In summary, 2010 was a very successful year for us, and we look forward to continued success in the year to come.

Our Recent Accomplishments Include:

Successful top-line results from our Phase 3 MARINE trial Completed patient randomization for our Phase 3 ANCHOR trial Strengthened management team and board of directors Strengthened balance sheet with additional $100M cash On track for a 2011 NDA submission

AMR101 is Positioned to Be Best-in-Class Therapy for Very High TriglyceridesIn November 2010, we announced that AMR101, Amarin's lead product candidate for the treatment of patients with very high triglycerides (>500 mg/dL), met the primary endpoint in the Phase 3 MARINE study with highly significant reductions in triglycerides from baseline compared to placebo at both the 4 gram and 2 gram doses. In addition to achieving these key endpoints, the results of this trial exceeded our expectations with no statistically significant increase in LDL-cholesterol observed at either dose, with triglyceride lowering that was greater in the predefined subset of patients on statin therapy and with encouraging results regarding prespecified markers of inflammation. Additionally, we observed in the trial a safety profile for AMR101 similar to placebo. The endpoints for this trial were establishe